Skip to main content

Table 1 Baseline characteristics of PLWH stratified by transmission category

From: A comparative analysis on characteristics and mortalities of four key transmission populations on antiretroviral therapy: a retrospective cohort study in Northwest China

 

All

Homosexuals

Heterosexuals

IDUs

Blood and plasma donors

Unknownb

P-valuec

Number

5942

4205

1358

85

23

271

 

Gender* [number (%)]

 Male

5535 (93.2)

4198 (99.8)

1034 (76.1)

72 (84.7)

18 (78.3)

213 (78.6)

 < 0.001

 Female

407 (6.8)

7 (0.2)

324 (23.9)

13 (15.3)

5 (21.7)

58 (21.4)

Marital statusa* [number (%)]

 Unmarried

2917 (49.1)

2433 (57.9)

402 (29.6)

27 (31.8)

7 (30.4)

48 (17.7)

 < 0.001

 Married

2173 (36.6)

1205 (28.7)

743 (54.7)

36 (42.4)

12 (52.2)

177 (65.3)

 Divorced

775 (13.0)

538 (12.8)

180 (13.3)

22 (25.9)

2 (8.7)

33 (12.2)

 Widowed

74 (1.20)

28 (0.7)

33 (2.4)

–

2 (8.7)

11 (4.1)

 Unknownb

3 (0.1)

1 (0.0)

–

–

–

2 (0.7)

Age at ART initiation*

 Years, median (IQR)

33 (27–44)

32 (26–42)

37 (29–48)

45 (39–48)

40 (30–56)

45 (33–57)

 < 0.001

Interval between diagnosis moment and ART initiation*

 Days, median (IQR)

33 (18–105)

33 (18–105)

33 (19–85)

603 (74–2005)

36 (15–1301)

33 (15–85)

 < 0.001

BMIa* (kg/ m2)

 Median (IQR)

21.5 (19.6–23.6)

21.5 (19.7–23.5)

21.6 (19.7–23.8)

20.2 (18.8–22.6)

22.6 (19.8–24.4)

21.1 (19.2–23.2)

0.002

CD4 + lymphocyte countsa* (/μL)

 Median (IQR)

295 (160–425)

311 (186–442)

265 (108–385)

250 (160–334)

280 (31–472)

196 (56–315)

 < 0.001

WHO clinical stagea* [number (%)]

 Stage I

2749 (46.3)

2056 (48.9)

544 (40.1)

36 (42.4)

14 (60.9)

99 (36.5)

 < 0.001

 Stage II

1175 (19.8)

836 (19.9)

272 (20.0)

18 (21.2)

4 (17.4)

45 (16.6)

 Stage III

991 (16.7)

690 (16.4)

239 (17.6)

16 (18.8)

3 (13.0)

43 (15.9)

 Stage IV

1027 (17.3)

623 (14.8)

303 (22.3)

15 (17.6)

2 (8.7)

84 (31.0)

Comorbiditiesa* [number (%)]

 With comorbidities

972 (16.4)

592 (14.1)

245 (18.0)

15 (17.6)

6 (26.1)

114 (42.1)

0.002

 Without comorbidities

4970 (83.6)

3613 (85.9)

1113 (82.0)

70 (82.4)

17 (73.9)

157 (57.9)

HbsAga [number (%)]

 Positive

327 (5.5)

222 (5.3)

86 (6.3)

3 (3.5)

3 (13.0)

13 (4.8)

0.136

 Negative

5019 (84.5)

3562 (84.7)

1138 (83.8)

69 (81.2)

17 (73.9)

233 (86.0)

 Unknownb

596 (10.0)

421 (10.0)

134 (9.9)

13 (15.3)

3 (13.0)

25 (9.2)

Anti-HCV antibodiesa [number (%)]

 Positive

168 (2.8)

115 (2.7)

44 (3.2)

3 (3.5)

1 (4.3)

5 (1.8)

0.475

 Negative

5149 (86.7)

3649 (86.8)

1175 (86.5)

70 (82.4)

19 (82.6)

236 (87.1)

 Unknownb

625 (10.5)

441 (10.5)

139 (10.2)

12 (14.1)

3 (13.0)

30 (11.1)

  1. PLWH people living with HIV, IDU injecting drug user, IQR interquartile range, ART antiretroviral therapy, BMI body mass index, HbsAg hepatitis B surface antigen and HCV, hepatitis C virus
  2. aMarital status, BMI, WHO clinical stage, CD4 + T lymphocyte counts, comorbidities and testing of HbsAg and anti-HCV antibodies were determined based on the date of ART initiation
  3. bPatients with missing data were included in the unknown group
  4. cP-values are calculated for comparisons among homosexuals, heterosexuals, IDUs and blood and plasma donors. Characteristics with statistically significant differences among the four transmission groups are selected for further analysis, which are indicated using a * in the superscript
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us